New shield for the vulnerable: antibody drug protects vaccine Non-Responders from omicron
NCT ID NCT07473986
First seen Apr 06, 2026 · Last updated May 15, 2026 · Updated 9 times
Summary
This study looked at whether a shot of Evusheld (two long-acting antibodies) could prevent COVID-19 in 88 immunocompromised people who did not make enough antibodies after vaccination. Participants were observed for symptomatic infections. The goal was to see if this preventive approach could protect those at high risk, such as organ transplant recipients, from severe COVID-19.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-COV-2 OMICRON VARIANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Pavia, 27100, Italy
Conditions
Explore the condition pages connected to this study.